Objective To evaluate the safety and efficacy of Shengmaiyin oral solution in promoting rapid recovery during the perioperative period in cancer patients and to explore its clinical value in enhanced recovery after surgery . Method From May 2023 to May 2024 400 cancer patients who underwent neoadjuvant chemotherapy were recruited from the Cancer Hospital of the Chinese Academy of Medical Sciences Shanxi Cancer Hospital Dongzhimen Hospital of Beijing University of Chinese Medicine and Guang' anmen Hospital of the China Academy of Chinese Medical Sciences. The patients were randomly divided into two groups. The experimental group received Shengmaiyin oral solution during the perioperative period on top of routine postoperative treatment. Primary outcomes included quality of life QOL scores on postoperative days 1 7 and 14. Secondary outcomes included the time to first flatus time to first defecation drainage tube removal time and length of hospital stay. Result The QOL scores on postoperative days 1 7 and 14 were significantly higher in the experimental group than in the control group P<0. 05 . The time to first flatus and first defecation in the experimental group was earlier than in the control group with statistically significant differences P<0. 05 . There was no statistically significant difference between the two groups in terms of drainage tube removal time and length of hospital stay P> 0. 05 . The incidence of adverse events was not significantly different between the two groups P>0. 05 . Conclusion Shengmaiyin oral solution combined with standard care can promote rapid recovery during the perioperative period in cancer patients undergoing neoadjuvant chemotherapy demonstrating good safety and efficacy.